PriceTargets.com logo

Meridian Bioscience - VIVO Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$33.97 As of 01/31/2023 01:00 AM ET
+0 (0.00%)
Get New Meridian Bioscience Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for VIVO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for VIVO

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Meridian Bioscience in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $33.97.

This chart shows the closing price for VIVO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in Meridian Bioscience. This rating has held steady since October 2023, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
6/30/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/28/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/27/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/24/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/22/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/21/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/21/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/25/2022William BlairReiterated RatingMarket Perform
7/8/2022HC WainwrightDowngradeBuy ➝ Neutral$30.00 ➝ $34.00
7/7/2022William BlairDowngradeOutperform ➝ Market Perform
5/27/2022HC WainwrightReiterated RatingBuy$30.00
4/8/2022HC WainwrightReiterated RatingBuy$30.00
2/7/2022HC WainwrightBoost TargetBuy$28.00 ➝ $30.00
11/15/2021HC WainwrightBoost TargetBuy$27.00 ➝ $28.00
10/8/2021HC WainwrightReiterated RatingBuy$27.00
8/9/2021HC WainwrightLower TargetBuy$30.00 ➝ $27.00
7/26/2021HC WainwrightReiterated RatingBuy$30.00
6/29/2021HC WainwrightReiterated RatingBuy$30.00
5/10/2021HC WainwrightLower TargetBuy$32.00 ➝ $30.00
2/24/2021HC WainwrightLower TargetBuy$34.00 ➝ $32.00
2/8/2021HC WainwrightReiterated RatingBuy$30.00 ➝ $34.00
2/8/2021Piper SandlerBoost TargetOverweight$26.00 ➝ $34.00
1/19/2021HC WainwrightReiterated RatingBuy$30.00
11/16/2020Piper SandlerBoost TargetOverweight$24.00 ➝ $26.00
11/16/2020HC WainwrightLower TargetBuy$34.00 ➝ $30.00
9/18/2020HC WainwrightReiterated RatingBuy$34.00
7/27/2020HC WainwrightInitiated CoverageBuy$34.00
5/11/2020William BlairUpgradeMarket Perform ➝ Outperform
2/8/2020William BlairReiterated RatingMarket Perform
(Data available from 12/21/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/25/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/23/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 1 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Meridian Bioscience logo
Meridian Bioscience, Inc. engages in the development, production, sale, and distribution of diagnostic products. Its platforms include molecular, immunoassay, urea breath, and blood chemistry. It operates through the Diagnostics and Life Science segments. The Diagnostics segment consists of manufacturing operations for infectious disease and blood chemistry products and the sale and distribution of diagnostics products domestically and abroad. The Life Science segment distributes bulk antigens, antibodies, polymerase chain reaction/ quantitative PCR reagents, nucleotides, competent cells, and bioresearch reagents used by researchers, agri-bio companies, and other diagnostic manufacturing companies. The company was founded by William J. Motto in 1976 and is headquartered in Cincinnati, OH.
Read More

Today's Range

Now: $33.97
Low: $33.97
High: $33.97

50 Day Range

MA: $33.70
Low: $33.00
High: $33.97

52 Week Range

Now: $33.97
Low: $20.35
High: $34.38

Volume

N/A

Average Volume

973,737 shs

Market Capitalization

$1.50 billion

P/E Ratio

35.02

Dividend Yield

N/A

Beta

0.23

Frequently Asked Questions

What sell-side analysts currently cover shares of Meridian Bioscience?

The following sell-side analysts have issued reports on Meridian Bioscience in the last year: StockNews.com.
View the latest analyst ratings for VIVO.

What is the current price target for Meridian Bioscience?

0 Wall Street analysts have set twelve-month price targets for Meridian Bioscience in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Meridian Bioscience in the next year.
View the latest price targets for VIVO.

What is the current consensus analyst rating for Meridian Bioscience?

Meridian Bioscience currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for VIVO.

What other companies compete with Meridian Bioscience?

Other companies that are similar to Meridian Bioscience include Merit Medical Systems, Haemonetics, DENTSPLY SIRONA, ICU Medical and QuidelOrtho. Learn More about companies similar to Meridian Bioscience.

How do I contact Meridian Bioscience's investor relations team?

Meridian Bioscience's physical mailing address is 3471 RIVER HILLS DRIVE, CINCINNATI OH, 45244. The company's listed phone number is (513) 271-3700 and its investor relations email address is [email protected]. The official website for Meridian Bioscience is www.meridianbioscience.com. Learn More about contacing Meridian Bioscience investor relations.